0000000000166827

AUTHOR

Provinciali L

showing 4 related works from this author

Preclinical phase of Alzheimer's disease: Guideline for recognition and study of patients with mild cognitive impairment

2002

mild cognitive impairment Alzheimer DiseaseSettore MED/26 - Neurologia
researchProduct

Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases

2013

Although it is still debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients underwent endovascular treatment (ET) of CCSVI. The objective of the study is to evaluate the outcome and safety of ET in Italian MS patients. Italian MS centers that are part of the Italian MS Study Group were all invited to participate to this retrospective study. A structured questionnaire was used to collect detailed clinical data before and after the ET. Data from 462 patients were collected in 33 centers. ET consisted of balloon dilatation (93 % of cases) or stent application. The mean follow-up duration after ET was 31 weeks. Mean…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosismedicine.medical_treatmentendovascular multiple sclerosis treatment venousDermatologyBalloon dilatationCohort StudiesSurveys and QuestionnairesMedicineHumansIn patientEndovascular treatmentAdverse effectBeneficial effectsbusiness.industryMultiple sclerosisEndovascular ProceduresStentBrainRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryPsychiatry and Mental healthTreatment OutcomeSpinal CordVenous InsufficiencySettore MED/26 - NeurologiaFemaleNeurology (clinical)businessMultiple sclerosis CCSVI Endovascular treatmentFollow-Up Studies
researchProduct

Preclinical dementia: an Italian multicentre study on amnestic mild cognitive impairment

2006

<i>Background:</i> Different rates and cognitive predictors of conversion to dementia have been reported in subjects with different kinds of mild cognitive impairment (MCI). <i>Methods:</i> A prospective, 24-month follow-up study, involving 269 subjects who strictly fulfilled criteria for the amnestic MCI. <i>Results:</i> Conversion rate to dementia was 21.4% per year. Seventy-nine out of the 83 individuals who developed dementia were affected by probable Alzheimer’s disease (AD). Among others, at the 24-month follow-up 24.1% were still affected by amnestic MCI, 13.3% had changed their neuropsychological profile of impairment and 17.2% were cognitively no…

Malemedicine.medical_specialtyClinical Dementia RatingCognitive NeuroscienceAudiologyPattern RecognitionNeuropsychological TestsCohort StudiesAlzheimer DiseasePredictive Value of TestsAlzheimer's disease Dementia Mild cognitive impairment NeurospychologymedicineDementiaMemory impairmentHumansMemory disorderProspective StudiesPsychiatryHumans; Alzheimer Disease; Disease Progression; Aged; Predictive Value of Tests; Cognition Disorders; Italy; Verbal Learning; Prospective Studies; Pattern Recognition Visual; Cohort Studies; Follow-Up Studies; Dementia; Neuropsychological Tests; Amnesia; Female; MaleAgedAlzheimer’s disease Mild cognitive impairment Dementia NeurospychologyCognitive disorderNeuropsychologyMild cognitive impairmentCognitionVerbal LearningAlzheimer's diseaseNeurospychologymedicine.diseasePsychiatry and Mental healthPattern Recognition VisualItalyDisease ProgressionFemaleSettore MED/26 - NeurologiaDementiaAmnesiaGeriatrics and GerontologyAlzheimer's diseasePsychologyCognition DisordersVisualFollow-Up Studies
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct